These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15071785)

  • 1. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
    Ewenstein BM; Collins P; Tarantino MD; Negrier C; Blanchette V; Shapiro AD; Baker D; Spotts G; Sensel M; Yi SE; Gomperts ED
    Semin Hematol; 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PubMed ID: 15071785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD; Collins PW; Hay CR; Shapiro AD; Gruppo RA; Berntorp E; Bray GL; Tonetta SA; Schroth PC; Retzios AD; Rogy SS; Sensel MG; Ewenstein BM;
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003; 4(6):366-8. PubMed ID: 14584967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
    Chen R; Gultyaev D; Lister J; Han R; Hu N; Malacan J; Solms A; Vashi P; O'Hara J; Hu S
    BMC Med Res Methodol; 2022 Aug; 22(1):215. PubMed ID: 35931967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIII concentrates.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2010 Jul; 36(5):493-7. PubMed ID: 20632247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
    Fernandez M; Yu T; Bjornson E; Luu H; Spotts G
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
    Josephson CD; Abshire T
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Symposium on Recombinant Factor VIII: report of the proceedings.
    Growe GH; Poon MC; Scarth I
    Transfus Med Rev; 1992 Apr; 6(2):137-45. PubMed ID: 1591490
    [No Abstract]   [Full Text] [Related]  

  • 15. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?
    Suiter TM
    Semin Thromb Hemost; 2002 Jun; 28(3):277-84. PubMed ID: 12098089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC; Courter S; Bray GL; Lee M; Gomperts ED
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E; Scharrer I
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.